Microviable Therapeutics is a biotech company at preclinical stage developing novel biological medicines for antimicrobial-resistant infectious diseases and oncology.
The development of our novel biological drugs is based on complex bacterial consortia naturally occurring in the human body (microbiome). Microviable’s drug development platform (PharmaBiota®), encompassing bioinformatics, microbiology, immunology and molecular biology, has already enabled the development of our three current assets, representing a core platform for the development of new products into novel therapeutic areas.
Microviable has received the European Seal of Excellence two times, together with numerous national recognitions and awards. Microviable has a growing IP portfolio, proprietary research facilities, a high-talented team of 19 individuals and a well-experienced advisory board.
Microviable has raised up to 6M € between private equity and competitive funding (national and european). We are now looking to stablish partnerships with pharma companies to bring our lead candidate MVT-201 into clinical trials and to rise a pre-SeriesA of 3M €.
Microviable Therapeutics is looking to rise 3M € as a pre-series A to bring the lead candidate MVT-201 into clinical trials in CRC and support OPEX including preclinical validation of another two assets.